BioLineRx launches new initiative

The new initiative is to be funded with a $6 million grant from Pan Atlantic Bank and Trust Ltd.

By JOSHUA FREEMAN
June 6, 2007 07:21

Drug development company BioLineRx on Tuesday launch its Early Development Program (EDP), a new initiative that aims to provide funding for early stage research and development of innovative therapeutics that have not yet achieved in-vivo proof of concept (proven results from animal testing). The new initiative is to be funded with a $6 million grant from Pan Atlantic Bank and Trust Ltd. BioLineRx CEO Morris Laster told The Jerusalem Post this marks the "moving [of] the industrial paradigm to the left." Whereas previously, companies would generally pick up on post in-vivo research begun by academics, the EDP aims to "get in the game before a company normally would" in order to position new research so that it is better suited to industry.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS